caa a22 4500 397593821 CHVBK 20200916193720.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.suppl_C.45 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_C.45 Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients [Elektronische Daten] [B. P. Vaudaux, J. Cherpillod, P. Dayer] Azithromycin levels in tonsillar and/or adenoid tissue were determined in children (1.6-7.5 years old) who were scheduled for surgical removal of their tonsils and/or adenoids. The children received azithromycin oral suspension lOmg/kg once daily for 3 days. Tissue samples were obtained during surgery 1 (n = 4), 2 (n = 5), 4 (n = 6), or 8 (n = 5) days after the last dose of azithromycin. Serum samples were also obtained from four children in each of these groups at the time of surgery. Mean tissue concentrations of azithromycin were 10.33 ± 3.01, 7.21 ± 4.04, 9.30 ± 3.74 and 1.49 ± 0.48 mg/kg, respectively, 1, 2, 4 and 8 days after the last dose. At the corresponding times, serum concentrations were markedly lower: 47.25 ± 19 19, 14.00 ± 8.45, 8.00 ± 2.16 and <4 μg/L, respectively. The mean tissue:serum concentration ratios were, 227 ± 54, 547 ± 184 and 956 ± 355, respectively, 1, 2 and 4 days after treatment. No adverse events attributable to azithromycin were observed in any of the 23 children who had received at least one dose of azithromycin. The study shows that levels of azithromycin in tonsillar and adenoid tissue were consistently higher than in serum and remained elevated up to 8 days after the end of dosing, supporting the use of a short-course (3-day), once-daily regimen of azithromycin in the treatment of upper respiratory tract infections. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Vaudaux B. P. Department of Paediatrics, Centre Hospitalier Universitaire Vaudois Lausanne aut Cherpillod J. Hôpital de l'Enfance Lausanne aut Dayer P. Division of Clinical Pharmacology, Hôpital Cantonal Universitaire de Genève Geneva, Switzerland aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 45-51 0305-7453 37<45 1996 37 jac https://doi.org/10.1093/jac/37.suppl_C.45 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-oxford NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_C.45 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vaudaux B. P. Department of Paediatrics, Centre Hospitalier Universitaire Vaudois Lausanne aut NATIONALLICENCE 700 1- Cherpillod J. Hôpital de l'Enfance Lausanne aut NATIONALLICENCE 700 1- Dayer P. Division of Clinical Pharmacology, Hôpital Cantonal Universitaire de Genève Geneva, Switzerland aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 45-51 0305-7453 37<45 1996 37 jac SWISSBIB 397593821